Trial Profile

PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rose bengal sodium (Primary) ; Dacarbazine; Talimogene laherparepvec; Temozolomide
Indications Malignant melanoma
Focus Registrational; Therapeutic Use
Sponsors Provectus Biopharmaceuticals

Most Recent Events

19 Jan 2022 Status changed to discontinued.
27 Sep 2021 According to Provectus Biopharmaceuticals media release, data from this study will be presented on two poster presentations at the SMR 2021 Congress (the Society for Melanoma Research annual meeting).
30 Sep 2019 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com